Guardant Health Stock Sees RS Rating Jump To 83

Blockhead
21 Nov 2024

On Wednesday, Guardant Health (GH) stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.

X
RS Line vs. RS Rating: Which Is The Better Stock Indicator?
See All Videos
NOW PLAYING RS Line vs. RS Rating: Which Is The Better Stock Indicator?

This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history reveals that the best stocks typically have an 80 or higher RS Rating as they begin their biggest runs.


Risk Management In The Stock Market: How Much Money To Invest Now


Is Guardant Health Stock A Buy?

Guardant Health stock is trying to complete a cup without handle with a 37.04 entry. See if the medical stock can break out in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.

The precision oncology company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 34%.

Guardant Health stock holds the No. 9 rank among its peers in the Medical-Services industry group. Hims & Hers Health (HIMS), Castle Biosciences (CSTL) and Quest Diagnostics (DGX) are among the top 5 highly rated stocks within the group.

YOU MAY ALSO LIKE:

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10